Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference
Biophytis SA (FP: ALBPS), a clinical-stage biotechnology company focused on age-related disease treatments, has announced its participation in the upcoming Biomed Forum organized by All Invest Securities. The event, scheduled for February 4, 2025 in Paris, is an annual healthcare sector conference that connects biotech and medtech companies with institutional investors. During the forum, Biophytis will have the opportunity to engage with French and European investors, provide company updates, and present its 2025 outlook.
Biophytis SA (FP: ALBPS), un'azienda biotecnologica in fase clinica focalizzata sul trattamento delle malattie legate all'età, ha annunciato la sua partecipazione al prossimo Biomed Forum organizzato da All Invest Securities. L'evento, programmato per il 4 febbraio 2025 a Parigi, è una conferenza annuale del settore sanitario che connette aziende biotech e medtech con investitori istituzionali. Durante il forum, Biophytis avrà l'opportunità di interagire con investitori francesi ed europei, fornire aggiornamenti sull'azienda e presentare le sue prospettive per il 2025.
Biophytis SA (FP: ALBPS), una empresa de biotecnología en etapa clínica centrada en el tratamiento de enfermedades relacionadas con la edad, ha anunciado su participación en el próximo Biomed Forum organizado por All Invest Securities. El evento, programado para el 4 de febrero de 2025 en París, es una conferencia anual del sector salud que conecta empresas de biotecnología y tecnología médica con inversionistas institucionales. Durante el foro, Biophytis tendrá la oportunidad de interactuar con inversionistas franceses y europeos, proporcionar actualizaciones de la empresa y presentar su perspectiva para 2025.
Biophytis SA (FP: ALBPS)는 노화 관련 질병 치료에 집중하는 임상 단계의 생명공학 회사로, All Invest Securities가 주최하는 Biomed Forum에 참여할 것이라고 발표했습니다. 이 행사는 2025년 2월 4일 파리에서 예정되어 있으며, 생명공학 및 의료 기술 회사와 기관 투자자들을 연결하는 연례 의료 산업 회의입니다. 포럼 동안 Biophytis는 프랑스 및 유럽 투자자와 소통하고, 회사 업데이트를 제공하며, 2025년 전망을 발표할 기회를 가지게 됩니다.
Biophytis SA (FP: ALBPS), une entreprise de biotechnologie en phase clinique axée sur les traitements des maladies liées à l'âge, a annoncé sa participation au prochain Biomed Forum organisé par All Invest Securities. L'événement, prévu pour le 4 février 2025 à Paris, est une conférence annuelle du secteur de la santé qui met en relation des entreprises de biotechnologie et de technologie médicale avec des investisseurs institutionnels. Lors du forum, Biophytis aura l'occasion d'échanger avec des investisseurs français et européens, de fournir des mises à jour sur l'entreprise et de présenter ses perspectives pour 2025.
Biophytis SA (FP: ALBPS), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Behandlung altersbedingter Krankheiten konzentriert, hat seine Teilnahme am bevorstehenden Biomed Forum, das von All Invest Securities organisiert wird, angekündigt. Die Veranstaltung, die für den 4. Februar 2025 in Paris geplant ist, ist eine jährliche Konferenz im Gesundheitssektor, die Biotech- und Medtech-Unternehmen mit institutionellen Investoren verbindet. Während des Forums wird Biophytis die Möglichkeit haben, mit französischen und europäischen Investoren in Kontakt zu treten, Unternehmensaktualisierungen bereitzustellen und seinen Ausblick für 2025 zu präsentieren.
- None.
- None.
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 27, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the Biomed Forum organized by All Invest Securities on February 4, 2025, in Paris.
The Biomed Forum is the annual event dedicated to the healthcare sector, fostering connections between biotech or medtech companies and institutional investors. This will be an opportunity for Biophytis to engage with French and European investors, share updates on the company's latest developments, and outline its outlook for 2025.
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start, and Duchenne muscular dystrophy, Phase 1-2 to be started), respiratory diseases (COVID-19, Phase 2-3 completed), and metabolic disorders (obesity, Phase 2 to be started). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
Contacts Biophytis
Relations Investisseurs
Investors@biophytis.com
US Investors
Pascal Nigen - Alpha Bronze
pnigen@alphabronzellc.com
Media contacts
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238467
FAQ
When is Biophytis (ALBPS) participating in the Biomed Forum 2025?
What will Biophytis present at the 2025 Biomed Forum?
Who organizes the Biomed Forum where Biophytis will present?
What type of investors will Biophytis meet at the Biomed Forum 2025?
